IL154240A0 - 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods - Google Patents

4-pyrimidinamine derivatives, pharmaceutical compositions and related methods

Info

Publication number
IL154240A0
IL154240A0 IL15424001A IL15424001A IL154240A0 IL 154240 A0 IL154240 A0 IL 154240A0 IL 15424001 A IL15424001 A IL 15424001A IL 15424001 A IL15424001 A IL 15424001A IL 154240 A0 IL154240 A0 IL 154240A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
related methods
pyrimidinamine derivatives
pyrimidinamine
derivatives
Prior art date
Application number
IL15424001A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL154240A0 publication Critical patent/IL154240A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15424001A 2000-08-08 2001-08-06 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods IL154240A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22379100P 2000-08-08 2000-08-08
PCT/US2001/024659 WO2002012198A2 (fr) 2000-08-08 2001-08-06 Derives 4-pyrimidinamines, compositions pharmaceutiques et procedes associes

Publications (1)

Publication Number Publication Date
IL154240A0 true IL154240A0 (en) 2003-07-31

Family

ID=22837982

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15424001A IL154240A0 (en) 2000-08-08 2001-08-06 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods

Country Status (16)

Country Link
US (3) US20030008883A1 (fr)
EP (1) EP1313713B1 (fr)
JP (1) JP2004505952A (fr)
CN (1) CN1468225A (fr)
AR (1) AR031601A1 (fr)
AT (1) ATE398109T1 (fr)
AU (1) AU2001281120A1 (fr)
BR (1) BR0113165A (fr)
CA (1) CA2419030A1 (fr)
DE (1) DE60134414D1 (fr)
HK (1) HK1054033A1 (fr)
IL (1) IL154240A0 (fr)
MX (1) MXPA03001226A (fr)
NZ (1) NZ524100A (fr)
WO (1) WO2002012198A2 (fr)
ZA (1) ZA200301868B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011472A (es) 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
CA2531490A1 (fr) * 2003-07-15 2005-02-03 Neurogen Corporation Analogues de pyrimidine-4-ylamine substitues constituant des ligands des recepteurs vanilloides
WO2005009980A1 (fr) * 2003-07-22 2005-02-03 Neurogen Corporation Analogues de pyridin-2-ylamine substitues
AU2004295050A1 (en) 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
AU2005212438A1 (en) * 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2564355C (fr) 2004-05-07 2012-07-03 Amgen Inc. Modulateurs de proteines kinases et procede d'utilisation
EP1763526B1 (fr) 2004-06-28 2009-06-24 Bayer Schering Pharma AG Pyrimidines 4,6-disubstituees et leur utilisation comme inhibiteurs des proteines kinases
EP1807418A2 (fr) * 2004-10-22 2007-07-18 Amgen, Inc Heterocycles azotes substitues comme ligands du recepteur vanilloide et leur utilisation comme medicaments
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
EP2554163A4 (fr) * 2010-03-26 2013-07-17 Univ Hokkaido Nat Univ Corp Agent de traitement thérapeutique de maladies neurodégénératives
BR112015003655A2 (pt) * 2012-08-23 2017-07-04 Virostatics Srl composto; uso de um composto; e composição farmacêutica
AU2014362231B2 (en) * 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2018352701A1 (en) * 2017-10-17 2020-06-04 Merck Patent Gmbh Pyrimidine ΤΒΚ/ΙΚΚE inhibitor compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068271A (en) * 1988-09-21 1991-11-26 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines compositions
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
BR9407799A (pt) * 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
EA002973B1 (ru) * 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
CA2315050C (fr) * 1998-10-16 2009-02-03 Suntory Limited Derives d'acide aminophenoxyacetique comme neuroprotecteurs
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体

Also Published As

Publication number Publication date
MXPA03001226A (es) 2004-09-10
EP1313713B1 (fr) 2008-06-11
ATE398109T1 (de) 2008-07-15
HK1054033A1 (zh) 2003-11-14
US20040006094A1 (en) 2004-01-08
DE60134414D1 (de) 2008-07-24
ZA200301868B (en) 2004-06-25
JP2004505952A (ja) 2004-02-26
AU2001281120A1 (en) 2002-02-18
BR0113165A (pt) 2003-07-15
AR031601A1 (es) 2003-09-24
WO2002012198A2 (fr) 2002-02-14
US20030008883A1 (en) 2003-01-09
WO2002012198A3 (fr) 2002-06-06
CN1468225A (zh) 2004-01-14
US20030212079A1 (en) 2003-11-13
EP1313713A2 (fr) 2003-05-28
NZ524100A (en) 2005-01-28
CA2419030A1 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
HUP0301146A3 (en) 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
DZ3313A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DZ3311A1 (fr) Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
HUP0204514A3 (en) Pyridinylimidazoles, pharmaceutical compositions containing them and their use
IL152448A0 (en) 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same
HUP0302997A3 (en) Phenylalanine derivatives with alpha4-integrin effect, pharmaceutical compositions containing them and their use
HUP0303069A3 (en) Imidazole derivatives, pharmaceutical compositions containing them and their use
IL151952A0 (en) Aminopyridine derivatives and pharmaceutical compositions containing the same
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
IL154096A0 (en) Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
PL356911A1 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
IL154240A0 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them
IL153487A0 (en) Pharmaceutical compositions and methods for use
IL153897A0 (en) Pharmaceutical compositions and methods for use
IL154986A0 (en) Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof